Sol Gel’s acne cream reduces marks in two late studies.
Sol Gel Technologies Ltd said its lead acne drug candidate, Twyneo, met the main goal of reducing marks in two late-stage studies.
Twyneo is a once-daily topical non-antibiotic acne cream containing a fixed-dose combination of encapsulated benzoyl peroxide and tretinoin.
Acne is a common skin disease that affects about 40 million to 50 million people in the United States, according to the American Academy of Dermatology.
Also read:
1. Rapamycin cream may slow ageing in human skin: Study
2. Zydus Cadila gets USFDA nod for Isosorbide Dinitrate tablets, Desonide Cream
